According to “Science”, on November 2, the US Food and Drug Administration officially approved an HIV prevention drug — a generic drug for injecting napavir. One dose of generic medicine provides protection from HIV infection for 6 months, and its Indian manufacturer Dr. Reddy Laboratories has promised to sell the drug for only $40 per person per year. This decision by US regulators is expected to speed up delivery of potent HIV prevention drugs in low-income countries with high infection rates. Lenapavir was developed by the US biopharmaceutical company Gilead, and the FDA approved it as a “pre-exposure prophylaxis” drug in June 2025. Two doses of the drug provide one year of protection and cost around $28,000. Gilead has previously agreed to supply lenapavir to the Global Foundation to Fight AIDS, Tuberculosis and Malaria at a non-profit price. According to sources, the price is $120 per person per year. The Global Foundation currently funds disease prevention and treatment efforts in more than 100 countries.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.